Findings Reported for FANTOM II Study of Reva Medical's Bioresorbable Scaffold


June 10, 2019—Twelve-month follow-up data from the FANTOM II study were published by Bernard Chevalier, MD, et al online in Circulation: Cardiovascular Interventions.

The purpose of this study was to evaluate the 9-month angiographic and 12-month clinical outcomes of the Fantom sirolimus-eluting bioresorbable coronary scaffold (Reva Medical, Inc.) in a larger patient population. The Fantom incorporates a radiopaque polymer, struts with a thickness of 125 µm, and a crossing profile of 1.35 mm.

The investigators concluded that the Fantom scaffold demonstrated favorable safety and effectiveness performance at 12-month follow-up. They advised that longer-term follow-up is ongoing to examine the late outcomes with this novel device.

The FANTOM II is the initial evaluation of the 24-month outcomes of the safety and performance of the Fantom device. The prospective, multicenter trial enrolled 240 patients with single de novo coronary stenosis with reference vessel diameter of 2.5 to 3.5 mm and lesion length ≤ 20 mm. Investigators assessed major adverse cardiac events through 12-month follow-up.

As summarized in Circulation: Cardiovascular Interventions, angiographic follow-up was performed in consecutive patient cohorts at 6 months (n = 117) and 9 months (n = 123). The results included the following, as defined in the clinical protocol: acute delivery success 97.9% (235/240); acute technical success 95.8% (230/240); acute procedural success 99.1% (228/230); and clinical procedural success rates 99.6% (227/228).

Additionally, the mean in-stent late lumen loss was 0.25 ± 0.40 mm at 6 months and 0.33 ± 0.36 mm at 9 months. In-segment binary restenosis occurred in 2% of patients at 6 months and 7.6% of patients at 9 months. Additionally, major adverse cardiac events and target lesion failure through 12 months occurred in 4.2% of the 240 patients; scaffold thrombosis developed in only one patient (0.4%), reported the investigators in Circulation: Cardiovascular Interventions.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.